# A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT07292714** · PHASE2 · RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease COPD

## Interventions

- **DRUG:** 9MW1911
- **DRUG:** Phase II placebo

## Key facts

- **NCT ID:** NCT07292714
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-12
- **Final completion:** 2028-02
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07292714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07292714, "A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07292714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*